Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of “Moderate Buy” by Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given an average recommendation of “Moderate Buy” by the twenty-four research firms that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $279.14.

A number of equities research analysts have issued reports on ALNY shares. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $198.00 to $370.00 in a research note on Friday, August 16th. Raymond James raised their price target on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Morgan Stanley increased their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. TD Cowen boosted their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, Needham & Company LLC increased their price target on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 2nd.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,491 shares of company stock worth $15,446,733. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Gilbert & Cook Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 7.7% in the 4th quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company’s stock worth $850,000 after purchasing an additional 317 shares in the last quarter. Commerce Bank grew its holdings in shares of Alnylam Pharmaceuticals by 1.7% during the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock valued at $896,000 after buying an additional 77 shares during the last quarter. Hsbc Holdings PLC grew its holdings in shares of Alnylam Pharmaceuticals by 25.6% during the fourth quarter. Hsbc Holdings PLC now owns 44,199 shares of the biopharmaceutical company’s stock valued at $8,470,000 after buying an additional 9,014 shares during the last quarter. Weiss Asset Management LP bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $228,000. Finally, Treasurer of the State of North Carolina raised its holdings in shares of Alnylam Pharmaceuticals by 0.9% in the 4th quarter. Treasurer of the State of North Carolina now owns 86,697 shares of the biopharmaceutical company’s stock worth $16,595,000 after acquiring an additional 740 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.7 %

Shares of ALNY opened at $269.53 on Friday. The stock has a market capitalization of $34.09 billion, a PE ratio of -100.57 and a beta of 0.38. The firm’s 50 day moving average is $265.33 and its 200-day moving average is $206.04. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same quarter in the previous year, the company posted ($2.21) earnings per share. The business’s revenue was up 107.0% compared to the same quarter last year. Equities research analysts predict that Alnylam Pharmaceuticals will post -2.73 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.